Extraskeletal Ewing's sarcoma family of tumors in adults: Prognostic factors and clinical outcome

Japanese Journal of Clinical Oncology

Volumn 42, Issue 5, 2012, Pages 420-426

  Tural, Deniz ^a   Molinas Mandel, Nil ^a   Dervisoglu, Sergulen ^a   Oner Dincbas, Fazilet ^a   Koca, Sedat ^a   Colpan Oksuz, Didem ^a   Kantarci, Fatih ^a   Turna, Hande ^a   Selcukbiricik, Fatih ^a   Hiz, Murat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Clinical outcome; Extraskeletal Ewing's sarcoma family of tumors in adults; Prognostic factors

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; EVENT FREE SURVIVAL; EWING SARCOMA; EXTRASKELETAL EWING SARCOMA; FEMALE; FOLLOW UP; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHYSICAL EXAMINATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; INCIDENCE; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SARCOMA, EWING; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 84860483744     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys027     Document Type: Article

References (32)

1. Delattre O, Zucman J, Plougastel B. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumors. Nature 1992;359:162.
2. Zucman J, Delattre O, Desmaze C. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Cancer 1992;5:271.
3. Ambros IM, Ambros PF, Strehl S. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 1991;67:1886-93.
4. Fellinger EJ, Garin-Chesa P, Triche TJ, Huvos AG, Rettig WJ. Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2. Am J Pathol 1991;139:317-25.
5. Glass AG, Fraumeni JF, Jr. Epidemiology of bone cancer in children. J Natl Cancer Inst 1970;44:187.
6. Miller RW. Contrasting epidemiology of childhood osteosarcoma, Ewing's tumor, and rhabdomyosarcoma. Natl Cancer Inst Monogr 1981;56:9-15.
7. Coffin CM, Dehner LP. Neurogenic tumors of soft tissue. In: Coffin CM, Dehner L, O'Shea PA, editors. Pediatric Soft Tissue Tumors: A Clinical, Pathological and Therapeutic Approach. Baltimore, MD, USA: Williams & Wilkins 1997;80-132.
8. Siegel RD, Ryan LM, Antman KH. Adults with Ewing's sarcoma: an analysis of 16 patients at the Dana-Farber Cancer Institute. Am J Clin Oncol 1988;11:614-7.
9. Sinkovics JG, Plager C, Ayala AG. Ewing sarcoma: its course and treatment in 50 adults patients. Oncology 1980;37:114-9.
10. Fizazi K, Dohollou N, Blay JY, Guérin S, Le Cesne A, André F, et al. Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol 1983;16:3736-43.
11. Granowetter L, West DC. The Ewing's sarcoma family tumors: Ewing's sarcoma and peripheral neuroectodermal tumor of bone and soft tissue. Rewiew. Cancer Treat Res 1997;92:253-308.
12. Angervall L, Enzinger FM. Extraskeletal neoplasm resembling Ewing's sarcoma. Cancer 1975;36:240-51.
13. Smith MA, Gurney JG, Ries LA. Cancer in adolescents 15 to 19 years old. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. NIH Pub. No. 99-4649. Bethesda, MD, 1999.
14. Grier HE, Krailo Mark D. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
15. Ahmad R, Mayol BR, Davis M. Extraskeletal Ewing's sarcoma. Cancer 1999;85:725-31.
16. Baldini EH, Demetri GD, Christopher DM, Fletcher CDM. Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg 1999;230:79-86.
17. Martin RCG, II, Brennan MF. Adult soft tissue ewing sarcoma or primitive neuroectodermal tumors. Arch Surg 2003;138:281-5.
18. Ramachandran V, Mathew KG, Ganapathy Ramanan S. A single institution experience of combined modality managementof extra skeletal Ewings sarcoma. World J Surg Oncol 2007;5:3.
19. El Weshi A, Allam A, Ajarim D. Extraskeletal Ewing's sarcoma family of tumours in adults: analysis of 57 patients from a single institution. Clin Oncol 2010;22:374-81.
20. Prestidge BR, Donaldson SS. Treatment results among adults with childhood tumors: a 20-year experience. Int J Radiat Oncol Biol Phys 1989;17:507-14.
21. Raney RB, Asmar L, Newton WA, Jr. Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991. J Clin Onclogy 1997;15:574-82.
22. Kinsella TJ, Triche TJ, Dickman PS. Extraskeletal Ewing's sarcoma: result of combined modality treatment. J Clin Onclogy 1983;1:489-95.
23. Rud NP, Reiman HM, Pritchard DJ. Extraoseous Ewing's sarcoma. A study of 42 cases. Cancer 1989;64:1548-53.
24. Sienbenrock KA, Nascimento AG, Rock MG. Comparison of soft tissue Ewing's sarcoma and peripheral neuroectodermal tumor. Clin Orthop 1996;329:288-99.
25. Verrill MW, Judson IR, Wiltshaw E. The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours. Ann Oncol 1997;8:1099-105.
26. Smeland S, Wiebe T, Brosjo O. Chemotherapy in Ewing's sarcoma. The Scandinavian Sarcoma Group experience. Acta Orthop Scand 2004;75:87-91.
27. Bacci G, Ferrari S, Longhi A. Prognostic significance of serum LDH in Ewing's sarcoma of bone. Oncol Rep 1999;6:807-11.
28. Bacci G, Ferrari S, Bertoni F. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000;18:4-11.
29. Picci P, Rougraff BT, Bacci G. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol 1993;11:1763-9.
30. Fizazi K, Blay JY, Guérin S, Le Cesne A, Tursz T, Nguyen BB. Localized Ewing tumor of bone: final results of the Cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001;19:1818-29.
31. Obata H, Ueda T, Kawai A. Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study. Cancer 2007;109:767-75.
32. Zagar TM, Triche TJ, Kinsella TJ. Extraosseous Ewing's sarcoma: 25 years later. J Clin Oncol 2008;26:4230-2.